These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 3622317)

  • 21. [Lack of tolerance development in interval therapy with 50 mg isosorbide-5-nitrate retard (Elantan long)].
    Jansen W; Prenzel R; Kümper H; Weidmann B; Tauchert M
    Z Kardiol; 1989; 78 Suppl 2():72-8; discussion 115-7. PubMed ID: 2511697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hemodynamic effects of isosorbide-5-mononitrate in coronary heart disease. A comparison of acute and chronic treatment].
    Wiechmann HW; Schuster P; Trieb G
    Dtsch Med Wochenschr; 1983 Sep; 108(35):1304-7. PubMed ID: 6884214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nitrate tolerance--can it be prevented?
    Parker JO
    Eur Heart J; 1991 May; 12 Suppl A():13-5. PubMed ID: 1874269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term haemodynamic effect of high doses of isosorbid dinitrate (80 mg) in slow-release form in coronary heart disease (author's transl)].
    Wolf R; Sinn R; Guillen R; Koeffler H
    Dtsch Med Wochenschr; 1981 Sep; 106(36):1130-4. PubMed ID: 7261938
    [No Abstract]   [Full Text] [Related]  

  • 25. Antianginal effect of isosorbide dinitrate spray in patients with exercise-induced stable angina.
    Aärynen M; Soininen K
    J Int Med Res; 1986; 14(6):303-5. PubMed ID: 3803701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can the problem of nitrate tolerance be solved?
    Silber S
    Z Kardiol; 1985; 74 Suppl 1():51-4. PubMed ID: 3993162
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
    Thadani U
    Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Equal anti-ischemic properties of isosorbide dinitrate plus verapamil and isosorbide dinitrate plus propranolol. A randomized, double-blind and crossover study.
    Silber S; Vogler A; Theisen K
    Z Kardiol; 1986; 75 Suppl 3():100-5. PubMed ID: 3541414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long term therapy of coronary heart disease with 120 mg slow release isosorbide dinitrate once a day. Study of duration of action and development of tolerance].
    Ohlmeier H; Mertens HM; Möller M; Mannebach H; Gleichmann U
    Z Kardiol; 1986; 75 Suppl 3():50-6. PubMed ID: 3541419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nitrate therapy without loss of action by correct dosage.
    Boertz A; Bonn R
    Z Kardiol; 1986; 75 Suppl 3():57-60. PubMed ID: 3798996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy.
    Mitrovic V; Gessner C; Hain P; Müller KD; Schlepper M
    Clin Cardiol; 1991 Mar; 14(3):209-18. PubMed ID: 1672843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of nitrate tolerance in patients with coronary heart disease by vascular ultrasonography and treadmill exercise.
    Yu GL; Zhuang HP; Wang ZH; Liao JT
    Int J Cardiol; 1999 May; 69(2):133-7. PubMed ID: 10549836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effectiveness of the delayed-action form of isosorbide 5-mononitrate in ischemic heart disease].
    Hůla J; Trhlíková M
    Vnitr Lek; 1991 Mar; 37(3):248-54. PubMed ID: 2031313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term nitrate therapy in coronary heart disease--loss of effect by developing tolerance].
    Dück KD; Richard F
    Z Gesamte Inn Med; 1990 Dec; 45(24):736-41. PubMed ID: 2129317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term percutaneous therapy of angina pectoris with isosorbide dinitrate with reference to isosorbide dinitrate blood levels].
    Kriehuber E; Prey T; Orthofer R
    Wien Med Wochenschr; 1982 Jun; 132(12):295-302. PubMed ID: 7123974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
    Parker JO
    Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
    Gunasekara NS; Noble S
    Drugs; 1999 Feb; 57(2):261-77. PubMed ID: 10188765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical relevance of nitrate hemodynamic attenuation.
    Flaherty JT
    Am Heart J; 1986 Jul; 112(1):216-20. PubMed ID: 3088959
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-ischemic effects of an 80-mg tablet of isosorbide dinitrate in sustained-release form before and after 2 weeks treatment with 80 mg once daily or twice daily.
    Silber S; Krause KH; Garner C; Theisen K; Jahrmärker H
    Z Kardiol; 1983; 72 Suppl 3():211-7. PubMed ID: 6666224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term tolerance and effect of isosorbide-5-mononitrate in comparison to isosorbide dinitrate (ISDN retard) in patients with coronary disease].
    Smolarz A; Seeliger S; Glocke M
    Med Welt; 1981 Apr; 32(14A):548-53. PubMed ID: 6787385
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.